Impeto Medical is a privately owned medical device company formed in June 2005. Its corporate headquarters are located in Paris, France. Two subsidiaries have been created: Beijing Impeto Medical in China and Impeto Medical Inc. in San Diego, U.S.
Impeto Medical has developed a patented technology that assesses sudomotor function through sweat gland activity. It is non-invasive and analyses the ability of sweat glands to release chloride ions in response to an electrochemical stimulus. Sweat conductances are then measured on the palms of the hands and the soles of the feet. The level of sweat gland activity is linked to the status of small nerve fibers innervating sweat glands. Small nerve neuropathy can be present in the early stages of diabetes and prediabetes.
Based on this technology, Impeto Medical has developed EZSCAN, a device that allows the screening of cardiometabolic risk. EZSCAN can be used for diabetes screening and to create a follow-up prevention plan.
Impeto Medical has recently launched SUDOSCAN+, a device for both the detection of diabetes complications and long-term management of the disease through preventative follow-ups and treatment plans.
In fact, diabetes can lead to serious complications such as retinopathy, nephropathy and neuropathy, respectively affecting the eyes, kidneys and nerves, as well as autonomic disorders causing cardiac diseases, erectile dysfunctions and gastroparesis.
Diabetic peripheral neuropathy is a common complication of diabetes, affecting 60 to 70% of diabetes patients. Peripheral neuropathy can lead to diabetic foot. Cardiac autonomic neuropathy, as it can lead to cardiovascular diseases, increases mortality.
Impeto Medical Inc. markets SUDOSCAN, a device assessing galvanic skin response to evaluate sympathetic nervous system behaviour.